Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MIMEDX (Nasdaq: MDXG) reported second quarter 2026 net sales of $64 million, down 35% from $98.6 million a year earlier. Surgical product revenue grew 15% year over year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes effective January 1.
Gross profit was $44.4 million with a 69% margin versus 81% a year ago. SG&A declined to $59.8 million, but higher bad debt expense contributed to a net loss of $14.8 million, compared with $9.6 million of net income in the prior-year quarter. Cash and cash equivalents were $135.8 million at June 30, 2026.
MIMEDX also agreed to acquire Sanara MedTech (Nasdaq: SMTI) for $35 per share in cash and stock, implying about $350 million enterprise value. Each Sanara share will receive $33.00 in cash plus 0.4735 MIMEDX shares, a 46% premium to Sanara’s 30-day VWAP. MIMEDX plans to fund the cash portion with cash on hand and a new $300 million term loan from Hayfin, and reaffirmed 2026 net sales guidance of $260–$290 million with full-year Adjusted EBITDA expected to approach breakeven.
MIMEDX (Nasdaq: MDXG) and Sanara MedTech (Nasdaq: SMTI) signed a definitive merger agreement under which MIMEDX will acquire all outstanding Sanara shares in a cash-and-stock deal valued at $35 per share, implying an enterprise value of about $350 million and a 46% premium to Sanara’s 30-day VWAP.
Sanara holders will receive $33.00 in cash plus 0.4735 MIMEDX shares per Sanara share. MIMEDX plans to fund the cash portion with cash on hand and a new $300 million term loan from Hayfin, replacing its existing credit facility. The companies expect the combination to nearly double MIMEDX’s surgical revenue, push 2027 combined revenue above $400 million with adjusted EBITDA margin over 20%, and generate over $20 million in run-rate cost synergies. The boards of both companies unanimously approved the deal, which is expected to close by year-end, subject to Sanara shareholder and regulatory approvals.
MiMedx (Nasdaq: MDXG) will release its operating and financial results for the second quarter ended June 30, 2026 after market close on Wednesday, July 29, 2026, followed by a webcast and conference call at 4:30 p.m. Eastern Time. U.S. investors can dial 877-407-6184, international investors 201-389-0877, using Conference ID 13761338. A webcast replay will be available for about 30 days on the company’s website.
MIMEDX (Nasdaq: MDXG) announced that senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN.
Interested investors are invited to request meetings with management through their Craig-Hallum representative.
MiMedx (Nasdaq: MDXG) announced the commercial launch of G4Derm Plus on May 8, 2026, with initial U.S. sales already delivered and exclusive U.S. distribution rights secured.
G4Derm Plus is a 510(k)-cleared, acellular flowable extracellular matrix using self-assembling peptide technology. The product supports revascularization, granulation, and re-epithelialization and serves as an antibacterial barrier. The product is available through Premier and Vizient GPO agreements for national hospital access.
MIMEDX (Nasdaq: MDXG) reported Q1 2026 net sales of $59 million, down 33% year-over-year, driven by a 60% decline in Wound sales while Surgical sales rose 13%.
The company cut 2026 net sales guidance to $260–$290 million and now expects ~breakeven Adjusted EBITDA for 2026; cash was $160 million at March 31, 2026.
MiMedx (Nasdaq: MDXG) will report first quarter 2026 operating and financial results for the period ended March 31, 2026, after market close on Wednesday, April 29, 2026. The senior management team will host a webcast and conference call beginning at 4:30 p.m. Eastern Time that day.
According to the company, U.S. and international dial‑in numbers and a conference ID are provided, and a replay will be available on the company website for approximately 30 days following the event.
MiMedx (Nasdaq: MDXG) announced a restructuring to reduce annual operating expenses by approximately $40 million and expects a one-time $4 million restructuring charge in Q2 2026. The company eliminated the Chief Operating Officer role and plans additional commentary with Q1 2026 results in late April.
Management said Surgical will receive further investment while Wound Care is recovering slowly after the January 1 Medicare reimbursement reduction.
MiMedx Group (Nasdaq: MDXG) will sponsor and present at two leading wound care conferences: SAWC Spring 2026 (April 8–12, Charlotte) and DLS 2026 (April 8–11, Washington, D.C.).
Activities include sponsored symposia, multiple poster and oral clinical presentations, and exhibit booths to showcase peptide-based and placental allograft wound-care technologies.
MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX on March 23, 2026, a lyophilized placental allograft composed of two chorion layers with an intact intermediate layer.
The company said CHORIOFIX is its thickest product to date, designed to improve handling, positioning and suturing, and has been added to the prospective randomized CAMPAIGN trial to evaluate performance versus standard of care in non-healing diabetic foot ulcers.